Arca
Skip to content
Tools
Tools

Label Changes: Enspryng (satralizumab)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Enspryng label DailyMed has published, from Genentech, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 11
  • Sections changed, version 15 to 16: 14

What changed from version 15 to version 16

Jun 24, 2026 to Oct 30, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged · 33 words added
  2. Dosage and administrationChanged · 159 words added, 28 removed
  3. Dosage forms and strengthsChanged · 39 words added, 20 removed
  4. Adverse reactionsChanged · 926 words added, 5 removed
  5. Use in specific populationsChanged · 25 words added
  6. DescriptionChanged · 172 words added, 97 removed
  7. Clinical pharmacologyChanged · 201 words added, 168 removed
  8. Clinical studiesChanged · 682 words added, 3 removed
  9. How suppliedChanged · 52 words added, 40 removed
  10. Patient counseling informationChanged · 6 words added
  11. Medication guideChanged · 49 words added, 3 removed
  12. Instructions for useChanged · 307 words added, 308 removed
  13. Instructions for useChanged · 583 words added, 597 removed
  14. PRINCIPAL DISPLAY PANEL - 180 mg/1.5 mL Autoinjector CartonNew section · 49 words added

Indications and usage

Changed33 words added
1 INDICATIONS AND USAGE
1.1 Neuromyelitis Optica Spectrum Disorder (NMOSD)
ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
1.2 Thyroid Eye Disease (TED)
ENSPRYNG is indicated for the treatment of thyroid eye disease (TED) regardless of TED activity or duration in adult patients.

Dosage and administration

Changed159 words added, 28 removed
13 unchanged lines
Prior to every use of ENSPRYNG, advise patients to consult with their healthcare professional (HCP) if they suspect an active infection, including localized infections. In case of active infection, delay use of ENSPRYNG until the infection is resolved [see Warnings and Precautions (5.1)].
Recommended Dosage for NMOSD
The recommended loading dosage of ENSPRYNG for the first three administrations is 120 mg by subcutaneous injection at Weeks 0, 2, and 4, followed by a maintenance dosage of 120 mg every 4 weeks.
Recommended Dosage for TED
The recommended dose is based on the patient's body weight, as shown in Table 1.
Table 1 ENSPRYNG Dosing Regimen Based on Body Weight for TED
Body Weight | 40 kg to less than or equal to 100 kg | Greater than 100 kg
** "0 weeks" refers to time of the first administration.
Loading Dose | |
Every 2 weeks for the first three administrations. Weeks 0, 2 and 4 | 120 mg | 180 mg
Maintenance Dose | |
From week 8 and every 4 weeks thereafter | 120 mg | 180 mg
The safety and effectiveness of ENSPRYNG have not been established in TED patients weighing less than 40 kg.
Missed Dose
If a dose of ENSPRYNG is missed for any reason other than increases in liver enzymes [see Dosage and Administration (2.4)], administer as described in Table 12.
Table 12 Recommended Dosage for Delayed or Missed Doses
Last Dose Administered | Recommended Dosage for Delayed or Missed Doses
Less than 8 weeks during the maintenance period or missed a loading dose | Administer 120the mgrecommended dose [see Recommended Dose (2.2.1 and 2.2.2)] by subcutaneous injection as soon as possible, and do not wait until the next planned dose. Maintenance period After the delayed or missed dose is administered, reset the dose schedule to every 4 weeks. Loading period If the second loading dose is delayed or missed, administer as soon as possible and administer the 3rd and final loading dose 2 weeks later. If the third loading dose is delayed or missed, administer as soon as possible and administer the 1st maintenance dose 4 weeks later.
8 weeks to less than 12 weeks | 120Administer mgthe recommended dose by subcutaneous injection at 0 and 2 weeks, followed by 120the mgrecommended dose every 4 weeks.
12 weeks or longer | 120Administer mgthe recommended dose by subcutaneous injection at 0, 2, and 4 weeks followed by 120the mgrecommended dose every 4 weeks.
2.3 Important Administration Instructions
2 unchanged lines
Prior to use, remove ENSPRYNG from the refrigerator and allow it to sit at room temperature outside of the carton for 30 minutes. Do not warm ENSPRYNG in any other way.
Inspect visually for particulate matter and discoloration prior to administration. ENSPRYNG solution should be clear and colorless to slightly yellow. Do not use ENSPRYNG if the solution is cloudy, discolored, contains particles, or if the prefilled syringe or the autoinjector appears to be damaged or has been dropped.
Instruct patients who are prescribed the prefilled syringe to inject the full amount (1 mL), which provides 120 mg of ENSPRYNG, according to the directions provided in the IFU.
5 unchanged lines
If associated with any bilirubin elevation, discontinue ENSPRYNG, and reinitiation is not recommended.
If not associated with any bilirubin elevation above the ULN, when the ALT or AST level has returned to the normal range and following a benefit-risk assessment of the patient, treatment with ENSPRYNG can be restarted per the schedule in Table 23. Table 23 Recommended Dosage for Restart of Treatment After Liver Transaminase Elevation Last Dose Administered Recommended Dosage for Restart of Treatment Less than 12 weeks Restart at a dosage ofthe 120recommended mgdosage by subcutaneous injection every 4 weeks [see Recommended Dose (2.2.1 and 2.2.2)]. 12 weeks or longer Restart at a dose ofthe 120recommended mgdosage by subcutaneous injection at Weeks 0 , 2, and 4, followed by arecommended dosage of 120 mg every 4 weeks. If treatment is restarted, the liver parameters must be closely monitored, and if any subsequent increase in ALT/AST and/or bilirubin above the ULN is observed, ENSPRYNG should be discontinued, and another reinitiation is not recommended.
Neutrophil Counts
1 unchanged line

Dosage forms and strengths

Changed39 words added, 20 removed
3 DOSAGE FORMS AND STRENGTHS
ENSPRYNG is a clear, and colorless to slightly yellow solution available as:
Injection: 120 mg/mL clear, and colorless to slightly yellow solution in single-dose prefilled syringe or single-dose autoinjector.
Injection: 120 mg/mL in single-dose prefilled syringe.
Injection: 120 mg/mL in single-dose autoinjector.
Injection: 180 mg/1.5 mL in single-dose autoinjector

Adverse reactions

Changed926 words added, 5 removed
7 unchanged lines
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.
Adverse Reactions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
The safety of ENSPRYNG in NMOSD was evaluated in two randomized, placebo-controlled clinical trials [Study 1 evaluated ENSPRYNG without concurrent immunosuppressive therapy (IST) and Study 2 evaluated ENSPRYNG with concurrent IST], which included 41 anti-AQP4 seropositive patients treated with ENSPRYNG in Study 1 and 26 anti-AQP4 seropositive patients treated with ENSPRYNG in Study 2 [see Clinical Studies (14)]. In the double-blind, controlled period, the median exposure time on ENSPRYNG treatment was approximately 2 years in Study 1 and approximately 3 years in Study 2. The median exposure time on placebo treatment was approximately 1 year in both Study 1 and Study 2.
Adverse reactions that occurred in Study 1 and Study 2 in more than 5% of patients treated with ENSPRYNG, and at a greater incidence than in patients who received placebo, are shown in Table 34 and Table 4, respectively5. The most common adverse reactions (15% or greater with ENSPRYNG in either) were nasopharyngitis, headache, upper respiratory tract infection, gastritis, rash, arthralgia, extremity pain, fatigue, and nausea.
Table 34 Adverse Reactions Occurring in 4 or More Patients Treated with ENSPRYNG and Greater Incidence than Placebo in Patients with NMOSD in Study 1
Adverse Reaction | ENSPRYNG (N = 41) % | PLACEBO (N = 23) %
11 unchanged lines
Fall | 10 | 4
Table 45 Adverse Reactions Occurring in 3 or More Patients Treated with ENSPRYNG and Greater Incidence than Placebo in Patients with NMOSD in Study 2
Adverse Reaction | ENSPRYNG + IST (N = 26) % | PLACEBO + IST (N = 26) %
5 unchanged lines
Pharyngitis | 12 | 8
Thyroid Eye Disease (TED)
The safety of ENSPRYNG in TED was evaluated in two phase III randomized, double-masked, placebo-controlled, multicenter clinical trials (Study 3 and Study 4) which included 131 patients treated with ENSPRYNG.
Adverse reactions that occurred in Study 3 and Study 4 in more than 5% of patients treated with ENSPRYNG, and at a greater incidence than in patients who received placebo, are shown in Table 6.
Table 6 Adverse Reactions Occurring in 5% or More of Patients Treated with ENSPRYNG and Greater Incidence than Placebo in Patients with TED (Study 3 and Study 4 Pooled Analysis)
Adverse Reaction | ENSPRYNG (N = 131) % | PLACEBO (N = 124) %
Upper respiratory tract infection | 5.3 | 2.4
Alanine aminotransferase increased | 5.3 | 0.8
Neutropenia was also reported with less than 5% occurrence.
Injection-Related Reactions
NMOSD
In Study 1 and Study 2, injection-related reactions were reported in 9% of patients treated with ENSPRYNG compared with 8% in patients receiving placebo. These reactions in the ENSPRYNG-treated patients were predominantly mild to moderate in severity, and most occurred within 24 hours after the injection. The most commonly reported systemic symptom was diarrhea. The reported local injection site reactions were pruritus, injection site reaction, and skin mass.
TED
In Study 3 and Study 4, injection-related reactions (IRR) were predominantly mild to moderate in severity. No serious IRRs were reported. The most frequently reported systemic symptoms were fatigue and headache, and the most commonly reported local injection site reaction was pruritus. The majority of these events did not require dose interruption or treatment discontinuation, with the exception of two cases (pruritus and injection site reaction) that resulted in the discontinuation of treatment. IRRs were generally self-limiting and resolved without specific treatment.
In an open label trial in healthy adults, in which a single injection of 180 mg/1.5 mL by autoinjector was compared to two injections of 60 mg/0.5 mL and 120 mg/1 mL by prefilled syringe, the most commonly reported local injection site reactions were erythema, edema, induration, and pain. All local injection site reactions were mild to moderate in severity and most were resolved within 24 hours.
Infections
NMOSD
In Study 1, the rate of patients with infections was 51 patients/100 patient-years (95% CI: 32, 78) in patients treated with ENSPRYNG compared with 108 patients/100 patient-years (95% CI: 52, 199) in patients receiving placebo. The rate of patients with serious infections was 5 patients/100 patient-years (95% CI: 1, 14) in patients treated with ENSPRYNG compared with 4 patients/100 patient-years (95% CI: 0, 21) in patients receiving placebo.
In Study 2, the rate of patients with infections was 168 patients/100 patient-years (95% CI: 100, 265) in patients treated with ENSPRYNG compared with 143 patients/100 patient-years (95% CI: 83, 229) in patients treated with placebo. The rate of patients with serious infections was 4 patients/100 patient-years (95% CI: 1, 15) in patients treated with ENSPRYNG compared with 10 patients/100 patient-years (95% CI: 2, 28) in patients receiving placebo.
TED
In Study 3 and Study 4 the rate of infections was lower in patients treated with ENSPRYNG [94.08 events/100 PY (95% CI: 71.07,122.17)] compared with patients receiving placebo [113.92 events/100 PY (95% CI: 86.93,146.64)]. The rate of serious infections was 0.00 events/100 PY (95% CI: 0,6.2) in patients treated with ENSPRYNG compared with 1.90 events/100 PY (95% CI: 0.05,10.58) in patients receiving placebo.
Laboratory Abnormalities
Decreased Neutrophil Count
NMOSD
Of the patients treated with ENSPRYNG, 10% had neutrophils below 1 × 109/L compared to 9% in placebo in Study 1. In Study 2, 15% of patients had neutrophils below 1 × 109/L compared to 4% in placebo. There was one patient in Study 1 treated with ENSPRYNG with neutrophil counts < 0.5 × 109/L, and one patient in Study 2 discontinued ENSPRYNG because of neutropenia.
TED
In Study 3 and Study 4, decreased neutrophil counts through Week 24 were observed in 28.2% of patients treated with ENSPRYNG compared with 9.7% of patients receiving placebo. Of these patients in the ENSPRYNG group, 2.3 % had neutrophil count decreased below 1 x 109/L compared to no patients in the placebo group. The decreased neutrophil counts were not associated with serious infections.
Decreased Platelet Count
NMOSD
In Study 1, a shift in platelet count decreases from normal at baseline to below the lower limit of normal (LLN) occurred in 26% of patients treated with ENSPRYNG compared to 5% of patients receiving placebo. In Study 2, decreases in platelet counts from normal at baseline to below the LLN occurred in 35% of patients treated with ENSPRYNG and in 17% of patients receiving placebo. None of the patients had a decrease in platelet count to less than 50 × 109/L.
TED
In Study 3 and Study 4, decreases in platelet count through Week 24 were reported in 8.4 % of patients treated with ENSPRYNG compared to 2.4% of patients receiving placebo. All decreases in the ENSPRYNG group were characterized by a platelet counts in the range of below the LLN to 75 × 109/L. In the placebo group, two patients experienced decreases in platelet counts to the range of <LLN to 75 × 109/L, and one patient experienced a decrease in platelet count to the range of <75 to 50 × 109/L. None of the patients had a decrease in platelet count to less than 50 × 10⁹/L, and decreases were not associated with bleeding events.
Elevated Liver Enzymes
NMOSD
In Study 1, increases from normal at baseline to above ULN in ALT or AST occurred in 43% and 25% of patients treated with ENSPRYNG, respectively, compared to 13% and 9% of patients receiving placebo. In Study 2, increases from normal at baseline to above the ULN in ALT or AST occurred in 8% and 8% of patients treated with ENSPRYNG, respectively, compared to 12% and 19% of patients receiving placebo.
In Study 1 and Study 2 combined, elevations of ALT or AST greater than 3 times the ULN occurred in 3% of patients treated with ENSPRYNG, compared to no patients treated with placebo. These elevations were not associated with increases in total bilirubin. One patient receiving ENSPRYNG in Study 2 had an elevation of ALT above 5 times the ULN, which was observed 4 weeks after initiation of therapy, normalizing 78 days after discontinuation of ENSPRYNG.
TED
In Study 3 and Study 4, elevations in ALT or AST through Week 24 occurred in 25.2% and 11.5% of patients treated with ENSPRYNG respectively, compared with 7.3% and 4.8% of patients receiving placebo. The majority of elevations were characterized by an elevation above ULN to 3 × ULN. One patient (0.8%) in the placebo group experienced an AST elevation of >3 to 5 × ULN. No transaminase elevations of > 5 to 20× ULN or > 20 × ULN were reported. Most events of ALT and AST elevation resolved without requiring dose modification or discontinuation of ENSPRYNG.
Elevations in ALT or AST were not associated with increase in total bilirubin. Overall post-baseline, liver function tests abnormalities were infrequent, predominantly of low grade and, with no evidence of drug-induced liver injury or hepatotoxicity.
Lipid Abnormalities
NMOSD
In Study 1 and Study 2, elevations in total cholesterol above 7.75 mmol/L (300 mg/dl) occurred in 12% and 15% of patients treated with ENSPRYNG, respectively, compared to no patients receiving placebo.
Elevations in triglycerides above 3.42 mmol/L (300 mg/dl) occurred in 27% and 12% of patients treated with ENSPRYNG in Study 1 and Study 2, respectively, compared to 13% and 8% of patients receiving placebo.
TED
In Study 3 and Study 4, increases in total cholesterol through Week 24 were reported in 19.8% of patients treated with ENSPRYNG compared with 9.7% of patients receiving placebo. Elevations in cholesterol above 7.75 mmol/L were observed in 9.2% of these patients treated with ENSPRYNG compared with 2.4% of corresponding patients receiving placebo.
Increases in triglycerides were through Week 24 reported in 33.6% of patients treated with ENSPRYNG compared with 27.4 % of patients receiving placebo. Elevations in triglycerides above 3.42 mmol/L were observed in 1.5% of patients treated with ENSPRYNG compared with 3.2% of patients receiving placebo. The elevations in lipid parameters did not require treatment discontinuation
Fibrinogen Levels
NMOSD
In Study 1, the median percent reduction in fibrinogen was 38% in patients treated with ENSPRYNG compared to 5% in patients receiving placebo. In Study 2, the median percent reduction in fibrinogen level was 33% in patients treated with ENSPRYNG compared to 0% in patients receiving placebo.
Complement Levels
NMOSD
In Study 1, the median percent reduction in the C3 and C4 components of complement was 23% and 50% in patients treated with ENSPRYNG, respectively, compared to 0% and 1% patients receiving placebo. In Study 2, the median percent reduction in the C3 and C4 components of complement was 20% and 53% in patients treated with ENSPRYNG, respectively, compared to 0% and 1% in patients receiving placebo.
Body Weight
NMOSD
In the pool of Studies 1 and 2, body weight increases of at least 7% from baseline occurred in 28% of patients treated with ENSPRYNG compared to 8% of patients receiving placebo.
2 unchanged lines
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of anti-satralizumab-mwge antibodies in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.
In NMOSD Study 1 and NMOSD Study 2, anti-drug-antibodies (ADAs) were observed in 73% and 38% of patients receiving ENSPRYNG in the double-blind period, respectively. The ability of these ADAs to neutralize satralizumab-mwge binding is unknown. Patients with higher body weight and lower exposure were more likely to develop ADAs (irrespective of treatment with IST). Exposure was lower in ADA positive patients. Although anti-satralizumab-mwge antibody development was not found to affect the efficacy of ENSPRYNG in these patients, the available data are too limited to make definitive conclusions. Immunogenicity does not have a clinically-relevant impact on safety. Based on the available information, neither dose interruption nor modification is warranted in those patients who develop ADAs.
In TED Study 3 and TED Study 4, anti-drug-antibodies (ADAs) were observed in 44.8% and 39.1% of patients receiving ENSPRYNG, respectively. The ability of these ADAs to neutralize satralizumab-mwge binding is unknown. ADA incidence is similar in the 120 mg (50 of 119, 42%) and 180 mg (5 of 12, 41.7%) dose groups. Exposure was lower in ADA positive patients. Immunogenicity does not appear to have a clinically-relevant impact on safety, efficacy or PD.

Use in specific populations

Changed25 words added
2 unchanged lines
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women with NMOSD exposed to ENSPRYNG during pregnancy. Healthcare providers are encouraged to register NMOSD patients and pregnant women with NMOSD are encouraged to register themselves by calling 1-833-277-9338.
Risk Summary
There are no adequate data on the developmental risk associated with the use of ENSPRYNG in pregnant women. In an animal reproduction study, no adverse effects on maternal animals or fetal development were observed in pregnant monkeys and their offspring, with administration of satralizumab-mwge at doses up to 50 mg/kg/week (see Data).
In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2 – 4% and 15 – 20%, respectively. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. ENSPRYNG should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.
Clinical Considerations
10 unchanged lines
8.5 Geriatric Use
Clinical studies of ENSPRYNG did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. However, population pharmacokinetic analyses in patients with NMOSD and TED did not show that age affected the pharmacokinetics of satralizumab-mwge [see Clinical Pharmacology (12.3)]. In general, caution should be used when dosing the elderly, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.

Description

Changed172 words added, 97 removed
1 unchanged line
Satralizumab-mwge is a recombinant humanized anti-human interleukin 6 (IL-6) receptor monoclonal antibody based on a human IgG2 framework. Each light chain and heavy chain consists of 214 and 443 amino acids, respectively. Satralizumab-mwge is a glycoprotein with an approximate molecular weight of 143 kDa and is produced by recombinant DNA technology in Chinese hamster ovary cells. The binding of satralizumab-mwge to the IL-6 receptor is pH-sensitive.
ENSPRYNG (satralizumab-mwge) injection for subcutaneous administration is supplied as a sterile, clear, colorless to slightly yellow solution with no preservative with an approximate pH of 6. ENSPRYNG is supplied in a single-dose 1.0 mL prefilled syringe with a needle safety device or a single-dose 1.0 mL autoinjector that contains a prefilled syringe. Each prefilled syringe or autoinjector delivers 1 mL of solution containing 120 mg satralizumab-mwge, L-arginine (26.1 mg), L-aspartic acid (pH adjustment), L-histidine (3.1 mg), poloxamer 188 (0.5 mg), and Water for Injection, USP.
ENSPRYNG (satralizumab-mwge) injection for subcutaneous administration is supplied as a sterile, clear, colorless to slightly yellow solution with no preservative, and with an approximate pH of 6. ENSPRYNG is supplied in a single-dose 1 mL prefilled syringe with a needle safety device or a single-dose 1 mL or 1.5 mL autoinjector that contains a prefilled syringe.
Each prefilled syringe delivers 1 mL of solution containing 120 mg satralizumab-mwge, L-arginine (26.1 mg), L-aspartic acid (pH adjustment), L-histidine (3.1 mg), poloxamer 188 (0.5 mg), and Water for Injection, USP.
Each prefilled autoinjector delivers either:
1 mL of solution containing 120 mg satralizumab-mwge, L-arginine (26.1 mg), L-aspartic acid (pH adjustment), L-histidine (3.1 mg), poloxamer 188 (0.5 mg), and Water for Injection, USP.
1.5 mL of solution containing 180 mg satralizumab-mwge, L-arginine (39.2 mg), L-aspartic acid (pH adjustment), L-histidine (4.65 mg), poloxamer 188 (0.75 mg), and Water for Injection, USP.

Clinical pharmacology

Changed201 words added, 168 removed
1 unchanged line
12.1 Mechanism of Action
The precise mechanism by which satralizumab-mwge exerts therapeutic effects in NMOSD and TED is unknown but is presumed to involve inhibition of IL-6-mediated signaling through binding to soluble and membrane-bound IL-6 receptors.
12.2 Pharmacodynamics
The relationship between any of the pharmacodynamic effects of ENSPRYNG and clinical outcomes in NMOSD and TED is unknown.
12.3 Pharmacokinetics
The pharmacokinetics of ENSPRYNG have been characterized both in Japanese and Caucasian healthy volunteers, and in NMOSD patients. The pharmacokinetics in NMOSD patients using the recommended dose were characterized using population pharmacokinetic analysis methods based on a database of 154 patients.
The pharmacokinetics of ENSPRYNG have been characterized in healthy volunteers, and in NMOSD and TED patients. Population pharmacokinetic analyses were performed on databases of 154 NMOSD patients and 131 TED patients.
ENSPRYNG's pharmacokinetics was best described by a two-compartment population pharmacokinetic model with parallel linear and target-mediated (Michaelis-Menten) elimination and first-order SC absorption. ENSPRYNG clearance and volume parameters allometrically scaled by body weight (through power function with the fixed power coefficient of 0.75 and 1 for clearance and volume parameters, respectively)
The pharmacokinetics of satralizumab-mwge following administration of ENSPRYNG by prefilled syringe or autoinjector were comparable.
The concentration-time course of ENSPRYNG in patients with NMOSD was accurately described by a two-compartment population pharmacokinetic model with parallel linear and target-mediated (Michaelis-Menten) elimination and first-order subcutaneous absorption. ENSPRYNG clearance and volume parameters allometrically scaled by body weight (through power function with the fixed power coefficient of 0.75 and 1 for clearance and volume parameters, respectively). Body weight was shown to be a significant covariate, with clearance and Vc for patients weighing 123 kg (97.5th percentile of the weight distribution) increased by 71.3% and 105%, respectively, compared to a patient weighing 60 kg.
SteadyIn patients with NMOSD using the recommended dose, steady state pharmacokinetics were achieved after the loading period (8 weeks) as follows [mean (±SD)]: Cmin: 19.7 (12.2) mcg/mL, Cmax: 31.5 (14.9) mcg/mL, and AUC: 737 (386) mcg.mL/day/mL.
In patients with TED using the recommended dose, steady state pharmacokinetics were achieved after the loading period (8 weeks) as follows (mean (±SD)): Cmin: 17.7 (9.64) mcg/mL, Cmax: 28.7 (11.3) mcg/mL and AUC: 666 (301) mcg.day/mL.
Absorption
The bioavailability of satralizumab-mwge was 85%.
The median time to maximum concentration (Tmax) at steady state was approximately 6 days based on population pharmacokinetic analyses. The bioavailability of satralizumab-mwge was 85%. In healthy subjects, the bioavailability of satralizumab was comparable following a single subcutaneous injection with the auto-injector and the prefilled syringes.
Distribution
1 unchanged line
Elimination
The total clearance of satralizumab-mwge is concentration-dependent. Linear clearance (accounting for approximately half of the total clearance at steady state using the recommended dose in NMOSD patients) is estimated to be 0.0601 L/day. The associated terminal t1/2 is approximately 30 days (range 22 – 37 days) based on data pooled from Study 1 and Studyall 2studies.
Metabolism
3 unchanged lines
Specific Populations
Population pharmacokinetic analyses in patients with NMOSD or with TED showed that age, gender, and race did not meaningfully influence the pharmacokinetics of satralizumab-mwge.
Patients with Renal or Hepatic Impairment
3 unchanged lines
Based on population pharmacokinetic analyses of the available data, the impact of commonly used small molecule drugs on the pharmacokinetics of satralizumab-mwge remains inconclusive.
Suppression of IL-6 signaling by treatment with ENSPRYNG, from the low baseline levels seen in Study 1NMOSD and StudyTED 2,Studies is expected to have a minor impact on exposure of concomitant medications metabolized by CYP450 enzymes. The clinical significance of this is unknown.

Clinical studies

Changed682 words added, 3 removed
14 CLINICAL STUDIES
14.1 Clinical Studies in NMOSD
The efficacy of ENSPRYNG for the treatment of NMOSD in adult patients was established in two studies. Study 1 was a randomized (2:1), placebo-controlled trial in 95 patients without concurrent IST (Study 1, NCT02073279) in which 64 patients were anti-AQP4 antibody positive and 31 patients were anti-AQP4 antibody negative.
9 unchanged lines
All potential relapses were adjudicated by a blinded Clinical Endpoint Committee (CEC). The primary efficacy endpoint for both studies was the time to the first CEC-confirmed relapse.
In Study 1, the time to the first CEC-confirmed relapse was significantly longer in ENSPRYNG-treated patients compared to patients who received placebo (risk reduction 55%; hazard ratio 0.45; p = 0.0184). In the anti-AQP4 antibody positive population, there was a 74% risk reduction; hazard ratio 0.26; p = 0.0014 (Table 57; Figure 1). There was no evidence of a benefit in the anti-AQP4 antibody negative patients.
In Study 2, the time to the first CEC-confirmed relapse was significantly longer in patients treated with ENSPRYNG compared to patients who received placebo (risk reduction 62%; hazard ratio 0.38; p = 0.0184). In the anti-AQP4 antibody positive population, there was a 78% risk reduction; hazard ratio 0.22; p = 0.0143 (Table 57; Figure 2). There was no evidence of a benefit in the anti-AQP4 antibody negative patients.
Table 57 Efficacy Results from Study 1 and Study 2 in anti-AQP4 Antibody Positive NMOSD Patients
| Study 1 | Study 2
8 unchanged lines
Figure 2 Study 2: Time to First CEC-Determined NMOSD Relapse in the Randomized Controlled Period in the ITT Population Anti-AQP4 Antibody Positive Patients
14.2 Clinical Studies in TED
The efficacy of ENSPRYNG for the treatment of thyroid eye disease (TED) was evaluated in two identical, randomized, double-masked, placebo-controlled, multicenter Phase 3 clinical trials (Study 3, NCT05987423 and Study 4, NCT06106828) in patients with TED. A total of 258 patients were enrolled in the two studies, of whom 255 received at least one dose of study treatment through Week 24 (131 patients received ENSPRYNG). Overall, 238 patients (92.2%) completed the studies through Week 24. Patient age ranged from 19 to 80 years (median age, 49.4 years).
The study population included patients with active, moderate-to-severe TED (76.7%) and patients with inactive TED (23.3%). Patients were required to have either:
a clinical diagnosis of active TED, defined as a Clinical Activity Score (CAS) ≥3 and proptosis ≥3 mm above normal in the study eye, or
a clinical diagnosis of stable, chronic inactive TED, defined as CAS <3 and proptosis ≥3 mm above normal.
All patients were required to be euthyroid at baseline or to have mild hypo- or hyperthyroidism (defined as free T3 and free T4 within 50% above or below the normal range at screening). Patients with prior surgical or biologic treatment for TED were excluded. In both studies, patients were randomized to receive ENSPRYNG at the recommended dose [see Dosage and Administration (2.2)] or placebo administered by subcutaneous injection at Weeks 0, 2, and 4, followed by dosing every 4 weeks through Week 20.
The primary efficacy endpoint was the proptosis responder rate at Week 24 in the active TED population. A proptosis responder was defined as a patient with a ≥2 mm reduction in proptosis in the study eye from baseline without deterioration (≥2 mm increase in proptosis) in the non-study eye (Table 8). Additional evaluations included signs and symptoms of TED, including orbital pain, gaze evoked orbital pain, eyelid swelling, eyelid erythema, conjunctival redness, chemosis, inflammation, clinical activity score and assessments of quality of life (functional vision and patient appearance). Efficacy results of satralizumab were generally consistent across pre-defined subgroups (e.g., age, gender, ethnicity, race, iris pigmentation, smoking status) for the proptosis responder rate.
Proptosis response in the active TED population at Week 24 was 52.9% in the ENSPRYNG group compared to 23.4% in the placebo group in Study 4. Study 3 did not meet its pre-specified primary efficacy endpoint at Week 24 compared to placebo (Table 8).
Table 8: Primary Efficacy Results at Week 24 in Study 3 and Study 4 among TED Patients
Efficacy Outcomes | Study 3 | Study 4
Enspryng (n=50) | Placebo (n=51) | Enspryng (n=48) | Placebo (n=49)
Proptosis response in active TED population% (n) | 49.0% | 31.2% | 52.9% | 23.4%
Difference 95.03% CI (p-value) | 17.9% (-1.6%, 37.3%) (0.07) | 28.9% (11.5%, 46.2%) (<0.01)
Efficacy was also evaluated in the overall TED population, including both active and inactive disease (Table 9). Proptosis response in the overall TED population at Week 24 was 46.9% in the ENSPRYNG group compared to 22.2% in the placebo group in Study 4. The proptosis response in the overall TED population in Study 3 was generally consistent with Study 4.
Table 9 Additional Efficacy Results from Study 4 in TED Patients
Efficacy Outcomes at Week 24 | Study 4
| Enspryng n/N (%) / mean | Placebo n/N (%) / mean
Proptosis response in overall TED population at Week 24 | 30/64 (46.9%) | 14/63 (22.2%)
Difference 95.03% CI (p-value) | 24.6% 9.4%, 39.8% (<0.01)
Proportion of patients with Grade ≥ 1 reduction/improvement in diplopia (active population) at Week 24 | 17/28 (60.7%) | 8/31 (25.8%)
Difference 95.03% CI (p-value) | 35.1% 11.0%, 59.3% (<0.01)
Change in proptosis (mm) in the study eye (active population) at Week 24 | 48 –1.97mm | 49 – 0.96mm
Difference 95.03% CI (p-value) | – 1.02% – 1.67%, 0.36% (<0.01)

How supplied

Changed52 words added, 40 removed
2 unchanged lines
ENSPRYNG (satralizumab-mwge) injection is available as a sterile, preservative-free, clear, colorless to slightly yellow solution for subcutaneous injection in a single-dose prefilled syringe (PFS) with needle safety device or a single-dose autoinjector.
ENSPRYNG prefilled syringe and autoinjector are not made with natural rubber latex. Each ENSPRYNG carton contains one single-dose 120 mg/mL prefilled syringe (NDC 50242-007-01) or one single-dose 120 mg/mL autoinjector (NDC 50242-007-55).
ENSPRYNG prefilled syringe and autoinjector are not made with natural rubber latex. Each ENSPRYNG carton contains either:
One single-dose 120 mg/mL prefilled syringe (NDC 50242‑007‑01)
One single-dose 120 mg/mL autoinjector (NDC 50242-007-55).
One single-dose 180 mg/1.5mL autoinjector (NDC 50242-005-01).
16.2 Storage and Handling
3 unchanged lines

Patient counseling information

Changed6 words added
19 unchanged lines
A puncture-resistant container for disposal of syringes should be used and should be kept out of the reach of children. Instruct patients or caregivers in the technique as well as proper prefilled syringe or autoinjector disposal, and caution against reuse of these items.
Pregnancy Exposure Registry for NMOSD
Encourage patients to enroll in the ENSPRYNG Pregnancy Registry if they become pregnant while taking ENSPRYNG for NMOSD. The Registry monitors fetal outcomes of pregnant women with NMOSD exposed to ENSPRYNG [see Use in Specific Populations (8.1)].

Medication guide

Changed49 words added, 3 removed
This Medication Guide has been approved by the U.S. Food and Drug Administration | IssuedRevised: 610/2026
MEDICATION GUIDE ENSPRYNG® (en-spryng) (satralizumab-mwge) injection, for subcutaneous use
What is the most important information I should know about ENSPRYNG? ENSPRYNG may cause serious side effects including: 1. Infections. ENSPRYNG can increase your risk of serious infections some of which can be life-threatening. Talk to your healthcare provider if you are being treated for an infection or call them right away if you think you have signs of an infection, with or without a fever, such as: chills, feeling tired, muscle aches, cough that will not go away or a sore throat. skin redness, swelling, tenderness, pain or sores on your body. diarrhea, belly pain, or feeling sick. burning when you urinate or urinating more often than usual. Your healthcare provider will check if you have an infection and treat it if needed before you start or continue to take ENSPRYNG. Your healthcare provider should test you for hepatitis and tuberculosis (TB) before you start taking ENSPRYNG. All required vaccinations should be completed before starting ENSPRYNG. People using ENSPRYNG should not be given 'live' or 'live-attenuated' vaccines. 'Live' or 'live-attenuated' vaccines should be given at least 4 weeks before you start ENSPRYNG. Your healthcare provider may recommend that you get a 'non-live' (inactivated) vaccine, such as some of the seasonal flu vaccines. If you plan to get a 'non-live' (inactivated) vaccine, it should be given, whenever possible, at least 2 weeks before you start ENSPRYNG. 2. Increased liver enzymes. Your healthcare provider should order blood tests to check your liver enzymes before and while you are taking ENSPRYNG. Your healthcare provider will tell you how often you will need to have these blood tests. Make sure you get all of your follow-up blood tests as ordered by your healthcare provider. Your healthcare provider will tell you if you need to wait to start ENSPRYNG if your liver enzymes are increased. 3. Low neutrophil count. ENSPRYNG can cause a decrease in your neutrophil counts in your blood. Neutrophils are white blood cells that help the body fight off bacterial infections. Your healthcare provider should order blood tests to check your neutrophil count while you are taking ENSPRYNG. See "What are the possible side effects with ENSPRYNG?"
What is ENSPRYNG? ENSPRYNG is a prescription medicine used to treat: neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 (AQP4) antibody positive. thyroid eye disease (TED) no matter how severe it is or how long a person has had it. It is not known if ENSPRYNG is safe and effective in children.
Do not take ENSPRYNG if you: are allergic to satralizumab-mwge or any of the ingredients in ENSPRYNG. See "What are the ingredients in ENSPRYNG?" at the end of this Medication Guide for a complete list of ingredients in ENSPRYNG. have an active hepatitis B infection. have active or untreated inactive (latent) TB.
Before you take ENSPRYNG, tell your healthcare provider about all of your medical conditions, including if you: have or think you have an infection. See "What is the most important information I should know about ENSPRYNG?" have liver problems. have ever had hepatitis B or are a carrier of the hepatitis B virus.. have had or have been in contact with someone with tuberculosis. have had a recent vaccination or are scheduled to receive any vaccination. are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if ENSPRYNG will harm your unborn baby. Pregnancy Registry: There is a registry for pregnant women who take ENSPRYNG for NMOSD. The purpose of this registry is to check the health of the pregnant mother and her baby. If you are pregnant or become pregnant while taking ENSPRYNG for NMOSD, talk to your healthcare provider about how you can join this pregnancy registry, or you may contact the registry at 1-833-277-9338 to enroll. are breastfeeding or plan to breastfeed. It is not known if ENSPRYNG passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take ENSPRYNG. Tell your healthcare provider about all the medicines you are taking, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How should I take ENSPRYNG? ENSPRYNG is provided as a solution in a single-dose, prefilled syringe of 120 mg/mL of satralizumab-mwge, or autoinjector of 120 mg/mL or 180 mg/1.5mL of satralizumab-mwge. See the Instructions for Use inside the carton for complete instructions for the right way to prepare and inject ENSPRYNG. ENSPRYNG is given by an injection under the skin (subcutaneously). If your healthcare provider decides that you or your caregiver can give your injections of ENSPRYNG, you or your caregiver should receive training on the right way to prepare and inject ENSPRYNG. Before injecting, wait 30 minutes for the ENSPRYNG prefilled syringe or autoinjector to reach room temperature. Use ENSPRYNG within 5 minutes of removing the cap or the needle may clog. Do not remove the cap until ready to inject. Always inject all of the medicine in the prefilled syringe or autoinjector. The first 3 injections (loading period) of ENSPRYNG are taken 1 time every 2 weeks. After this, injection of ENSPRYNG is taken every 4 weeks (maintenance period). Keep taking ENSPRYNG 1 time every 4 weeks for as long as your healthcare provider tells you to. If you miss a dose of ENSPRYNG, talk to your health care provider about restarting dosing.
What are the possible side effects of ENSPRYNG? ENSPRYNG may cause serious side effects, including: See "What is the most important information I should know about ENSPRYNG?" Serious allergic reactions. Serious allergic reactions that may be life-threatening have happened with other medicines like ENSPRYNG. Tell your healthcare provider before taking your next dose if you had hives, rash, or flushing after your injection. Seek medical attention right away if you have any symptoms of a serious allergic reaction, such as:
3 unchanged lines
These are not all the possible side effects of ENSPRYNG. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.
How should I store ENSPRYNG? Store ENSPRYNG in the refrigerator between 36°F to 46°F (2°C to 8°C) in the original carton. Protectto protect from light. Do not freeze. Do not use ENSPRYNG if it has been frozen. Do not shake. The ENSPRYNG carton can be stored at room temperature up to 86°F (30°C) for up to 8 days. If ENSPRYNG is removed from and returned to the refrigerator the total combined time out of the refrigerator should not be more than 8 days. Always keep in the original carton to protect from light. Keep ENSPRYNG and all medicines out of the reach of children.
General information about the safe and effective use of ENSPRYNG. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ENSPRYNG for a condition for which it was not prescribed. Do not give ENSPRYNG to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ENSPRYNG that is written for health professionals.
1 unchanged line

Instructions for use

Changed307 words added, 308 removed
3 unchanged lines
Your healthcare provider will show you or your caregiver how to use the ENSPRYNG syringe the right way. Talk to your healthcare provider if you have any questions.
Important Informationinformation you need to know before injecting ENSPRYNG
Do not use the ENSPRYNG prefilled syringe until your healthcare provider has trained you or your caregiver on the right way to inject.
Do not share your ENSPRYNG syringe with other people. You may give them a serious infection or get a serious infection from them.
Do not use if the expiration (EXP) date has passed.
Do not use if the sealseals on the carton have been broken.
Do not try to take the syringe apart at any time.
4 unchanged lines
How should I store the ENSPRYNG prefilled syringe?
Store ENSPRYNG prefilled syringe in the refrigerator between 36°F to 46°F (2°C to 8°C) untilin readythe original carton to useprotect from light.
The ENSPRYNG carton can be stored at room temperature up to 86°F (30°C) for up to 8 days. If ENSPRYNG is removed from and returned to the refrigerator, the total combined time out of refrigeration should not be more than 8 days.
Keep the syringe in its original carton away from direct sunlight.
Always keep the syringe dry.
Do not freeze ENSPRYNG. Do not use the prefilled syringeENSPRYNG if it has been frozen.
Do not shake.
Throw away (dispose of) the prefilled syringe if it has been frozen, exposed to light or temperatures above 86°F (30°C), or has been out of the refrigerator for more than 8 days.
The ENSPRYNG carton can be stored at room temperature up to 86°F (30°C) for up to 8 days.
If ENSPRYNG is removed from and returned to the refrigerator the total combined time out of the refrigerator should not be more than 8 days.
Always keep in the original carton to protect from light.
Keep the ENSPRYNG syringe and all medicines out of the reach of children.
Supplies needed to give your injection
11 unchanged lines
Prepare to use ENSPRYNG
Step 1. | Take the carton containing the syringe out of the refrigerator and place it on a clean, flat work surface (like a table).
Step 2. | Check the expiration (EXP) date on the back of the carton (See Figure C). Do not use if the expiration date has passed.
3.Check the front of the carton to make sure it is sealed (Figure C). Do not use if the seal has been broken.
Step 3. | Check the front of the carton to make sure it is sealed (Figure C). Do not use if the seal has been broken. If the expiration date has passed or the seal is broken, do not use. Then go to Step 21 "Disposing of ENSPRYNG" and contact your healthcare provider.
If the expiration date has passed or the seal is broken, do not use. Then go to Step 21 "Disposing of ENSPRYNG" and contact your healthcare provider.
Step 4. | Open the sealed carton (See Figure D).
Step 5. | Carefully lift the syringe out of the carton by holding the barrel (See Figure E). Do not: turn the carton upside down to remove the syringe. Do not touch the activation guards because this may damage the syringe. Do not hold the plunger or needle cap.
Check the syringe
(See Figure F)
Step 6. | Check the expiration date on the syringe. Do not use the syringe if it has expired.
Step 7. | Check the syringe for any damage. Do not use if it is cracked or broken.
Step 8. | Check that the liquid through the viewing window is clear and colorless to slightly yellow. Do not inject the medicine if the liquid is cloudy, discolored, or has particles in it. There may be some small air bubbles in the syringe. This is normal and you should not try to remove them.
If the expiration (EXP) date has passed, the syringe is damaged or the liquid is cloudy, discolored or has particles in it, do not use. Then go to Step 21 "Disposing of ENSPRYNG" and contact your healthcare provider.
Let your syringe reach room temperature
Step 9. | After you have checked the syringe, place it on a clean, flat work surface (like a table) for 30 minutes. This will allow it to reach room temperature. (See Figure G). It is important to let the syringe gently warm to room temperature as injecting cold medicine may feel uncomfortable and make it harder to push. Do not: speed up the warming process in any way, such as using a microwave or placing the syringe in warm water. Do not remove the needle cover while the syringe is reaching room temperature.
Wash your hands
Step 10. | Wash your hands with soap and water. (See Figure H).
Choose the injection site
11.Choose your injection site in either: the lower part of your stomach (abdomen) or the front and middle of your thighs. (See Figure I). Do not inject into the 2-inch (5 cm) area around your belly button. Do not inject into moles, scars, bruises, or areas where the skin is tender, red, hard or broken.
Step 11. | Choose your injection site in either: the lower part of your stomach (abdomen) or the front and middle of your thighs. (See Figure I).
| Do not inject into the 2-inch (5 cm) area around your belly button. Do not inject into moles, scars, bruises, or areas where the skin is tender, red, hard or broken.
Choose a different injection site for each new injection. Choose a different place to inject which is at least 1 inch (2.5 cm) away from the place where you last injected.
Clean the injection site
Step 12. | Wipe the injection site with an alcohol pad and let it air dry (See Figure J). Do not: fan or blow on the area which you have cleaned. Do not touch the injection site again before you give the injection.
Inject ENSPRYNG
Step 13. | Hold the barrel of the syringe between your thumb and index finger. With your other hand, pull the needle cap straight off. You may see a drop of liquid at the end of the needle. This is normal and will not affect your dose (See Figure K). Use the syringe within 5 minutes of removing the cap or the needle may clog. Do not: take the needle cap off until you are ready to inject ENSPRYNG. Do not put the needle cap back on after it has been removed as this may damage the needle. Do not touch the needle or let it touch any surfaces after removing the needle cap.
Step 14. | Throw away the needle cap in a puncture-resistant sharps container immediately. See Step 21 "Disposing of ENSPRYNG".
Step 15. | Hold the barrel of the syringe using your thumb and index finger. With your other hand, pinch the area of skin you have cleaned (See Figure L).
Step 16.: | Use a quick, dart-like motion to insert the needle at an angle between 45° to 90° (See Figure L). Do not: insert the needle through clothing. Do not change the angle of the injection. Do not insert the needle again.
Step 17.: | After the needle is inserted, let go of the pinched skin.
Step 18.: | Slowly inject all of the medicine by gently pushing the plunger all the way down until it touches the activation guards (See Figure M).
19.Gently release the plunger and allow the needle to come out of the skin at the same angle it was inserted (See Figure N). The needle will now be covered by the needle-shield. If the needle is not covered, carefully place the syringe into a puncture-resistant sharps container to avoid injury. See Step 21 "Disposing of ENSPRYNG".
Step 19: | Gently release the plunger and allow the needle to come out of the skin at the same angle it was inserted (See Figure N).
| The needle will now be covered by the needle-shield. If the needle is not covered, carefully place the syringe into a puncture-resistant sharps container to avoid injury. See Step 21 "Disposing of ENSPRYNG".
Taking care of the injection site
Step 20.: | There may be a little bleeding at the injection site. You can press a cotton ball or gauze over the injection site but do not rub it. If needed, you may also cover the area you injected with a small bandage. If the medicine gets into contact with your skin, wash the area with water.
Disposing of ENSPRYNG
Step 21: | Put your used syringe in an FDA-cleared sharps disposal container immediately after use (See Figure O). Do not throw away (dispose of) the syringe in your household trash.
21.Put your used syringe in an FDA-cleared sharps disposal container immediately after use (See Figure O). Do not throw away (dispose of) the syringe in your household trash.| If you do not have an FDA-cleared sharps disposal container, you may use a household container that is: made of heavy-duty plastic can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out upright and stable during use leak-resistant properly labeled to warn of hazardous waste inside the container When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about the safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal. Do not dispose of your used sharps disposal container in trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
1 unchanged line
U.S. License No.: 1048
Approved: 6/2026
Revised: 10/2026
ENSPRYNG® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
1 unchanged line

Instructions for use

Changed583 words added, 597 removed
3 unchanged lines
Important information you need to know before injecting ENSPRYNG
Do not use the ENSPRYNG autoinjector until your healthcare provider has trained you or your caregiver on the right way to inject.
Do not use if the expiration (EXP) date has passed.
7 unchanged lines
How should I store the ENSPRYNG autoinjector?
Store ENSPRYNG autoinjector in the original carton in the refrigerator between 36°F to 46°F (2°C to 8°C) untilin readythe original carton to useprotect from light.
The ENSPRYNG carton can be stored at room temperature up to 86°F (30°C) for up to 8 days. If ENSPRYNG is removed from and returned to the refrigerator, the total combined time out of the refrigerator should not be more than 8 days.
Keep the autoinjector in the original carton away from direct sunlight.
Do not freeze ENSPRYNG. Do not use the autoinjectorENSPRYNG if it has been frozen.
Do not shake.
Throw away (dispose of) the autoinjector if it has been frozen, exposed to light or temperatures above 86°F (30°C), or has been out of the refrigerator for more than 8 days.
The ENSPRYNG carton can be stored at room temperature up to 86°F (30°C) for up to 8 days.
If ENSPRYNG is removed from and returned to the refrigerator the total combined time out of the refrigerator should not be more than 8 days.
Always keep in the original carton to protect from light.
Keep ENSPRYNG and all medicines out of the reach of children.
4 unchanged lines
Prepare to use ENSPRYNG
Step 1. | Gather supplies needed for your injection.
Included in the carton:
4 unchanged lines
1 small adhesive bandage
1 FDA-cleared sharps disposal container (See Step 17 Dispose of the autoinjector)
Remove the autoinjector
Step 2. | Take the ENSPRYNG autoinjector carton out of the refrigerator.
Step 3. | Open the carton and take the autoinjector out of the tray.
Check the autoinjector
4 Check the expiration (EXP) date on the autoinjector.
Step 4. | Check the expiration (EXP) date on the autoinjector. Do not inject if the expiration date (EXP) has passed.
Do not inject if the expiration date (EXP) has passed.
5 Check the medicine through the viewing window. The medicine should be clear or slightly yellow. There should be no particles in it.
Step 5. | Check the medicine through the viewing window. The medicine should be clear or slightly yellow. There should be no particles in it. Do not inject if the medicine looks cloudy, discolored, or has particles in it. You may see small air bubbles. This is normal and you should not try to remove them.
Do not inject if the medicine looks cloudy, discolored, or has particles in it. You may see small air bubbles. This is normal and you should not try to remove them.
6 Check the autoinjector for any damage.
Step 6. | Check the autoinjector for any damage. Do not use if the autoinjector is cracked or broken.
Do not use if the autoinjector is cracked or broken.
If the expiration date has passed, the autoinjector is damaged or the medicine is cloudy, discolored or has particles in it, do not use. Safely throw away (dispose of) the autoinjector in aan FDA-cleared sharps disposal container (See Step 17) and contact your healthcare provider.
Let your autoinjector reach room temperature
Step 7. | Place the autoinjector on a clean, flat surface (like a table) for 30 minutes. This allows the medicine to reach room temperature. If the autoinjector does not reach room temperature, it may take longer to inject the medicine. Injecting cold medicine may feel uncomfortable. Do not speed up the warming process in any way, such as using a microwave, warm water, or direct sunlight. Do not remove the cap until you are ready to inject.
Do not speed up the warming process in any way, such as using a microwave, warm water, or direct sunlight.
Do not remove the cap until you are ready to inject.
Choose the injection site
8 You can inject ENSPRYNG in the stomach area (abdomen) or front of the thigh.
Step 8. | You can inject ENSPRYNG in the stomach area (abdomen) or front of the thigh. Do not inject into the 2 inches (5 cm) area around the belly button. Do not inject into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact.
Do not inject into the 2 inches (5 cm) area around the belly button.
Do not inject into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact.
Choose a different injection site for each new injection. Each injection must be at least 1 inch (2.5 cm) away from area where you last injected.
Clean your skin
Step 9. | Wash your hands with soap and water.
10 Clean the injection site with an alcohol pad and let it air dry.
Step 10. | Clean the injection site with an alcohol pad and let it air dry. Do not fan or blow on the area you have cleaned. Do not touch the injection site again before you inject.
Do not fan or blow on the area you have cleaned.
Do not touch the injection site again before you inject.
Remove the cap
Step 11. | Hold the autoinjector with the cap pointing up. Then pull the cap straight off. The needle will remain hidden. Use the autoinjector within 5 minutes of removing the cap.
| Important: Do not touch the green needle shield. This may cause a needle stick injury.
Important: | Do not touch the green needle shield. This may cause a needle stick injury. Do not clean the green needle shield. This may activate the autoinjector. Do not put the cap back on after it has been removed. This may activate the autoinjector.
Do not clean the green needle shield. This may activate the autoinjector.
Do not put the cap back on after it has been removed. This may activate the autoinjector.
Place onto the skin
Step 12. | Hold the autoinjector so that you can see the viewing window. Place the autoinjector flat against the skin with the green needle shield facing down. You may see drops of liquid. This is normal. Do not change the angle of the injection.
Do not change the angle of the injection.
Push firmly and hold in place
13 Push firmly and hold down the autoinjector against the skin. The first click indicates the injection has started.
Step 13. | Push firmly and hold down the autoinjector against the skin. The first click indicates the injection has started. The green plunger moves down in the viewing window. It might take up to 15 seconds for the green plunger to move all the way down and fill the viewing window. Do not lift the autoinjector if the green plunger is moving. This may cause a loss of medicine.
The green plunger moves down in the viewing window. It might take up to 15 seconds for the green plunger to move all the way down and fill the viewing window.
Do not lift the autoinjector if the green plunger is moving. This may cause a loss of medicine.
14 Keep holding down the autoinjector firmly. Wait for the second click. This means the injection is done.
Step 14. | Keep holding down the autoinjector firmly. Wait for the second click. This means the injection is done. Watch the green plunger as it moves down. Or check if the green plunger has already filled the entire viewing window (See Step 15).
Watch the green plunger as it moves down. Or check if the green plunger has already filled the entire viewing window (See Step 15).
Check the green plunger
15 Before removing the autoinjector from the injection site, check that the green plunger fills the viewing window entirely.
Step 15. | Before removing the autoinjector from the injection site, check that the green plunger fills the viewing window entirely. If the green plunger does not fill the viewing window, you may not have received the full dose. Safely throw away (dispose of) the autoinjector in a sharps disposal container (See Step 17) and contact your healthcare provider.
If the green plunger does not fill the viewing window, you may not have received the full dose. Safely throw away (dispose of) the autoinjector in a sharps disposal container (See Step 17) and contact your healthcare provider.
Remove the autoinjector
16 Remove the autoinjector by lifting it straight up from the skin.
Step 16. | Remove the autoinjector by lifting it straight up from the skin. The green needle shield will lock into place, covering the needle when the injection is complete.
The green needle shield will lock into place, covering the needle when the injection is complete.
Dispose of the autoinjector
17 Put the used autoinjector and the cap in an FDA-cleared sharps disposal container right away after use.
Step 17. | Put the used autoinjector and the cap in an FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) the autoinjector in your household trash.
Do not throw away (dispose of) the autoinjector in your household trash.
Check the injection site
Step 18. | There may be a small amount of blood or medicine at the injection site. You can press a cotton ball or gauze on the area. If needed, cover the injection site with a small adhesive bandage. The injection is now complete. Do not rub or massage the area where you have injected.
Do not rub or massage the area where you have injected.
Disposal of the autoinjector
9 unchanged lines
This Instructions for Use has been approved by the U.S. Food and Drug Administration
Approved: 6/2026
Revised: 10/2026

PRINCIPAL DISPLAY PANEL - 180 mg/1.5 mL Autoinjector Carton

New section49 words added
PRINCIPAL DISPLAY PANEL - 180 mg/1.5 mL Autoinjector Carton
NDC 50242-005-01
Enspryng® (satralizumab-mwge) Injection
180 mg/1.5 mL
For Subcutaneous Use.
ATTENTION PHARMACIST: Each patient is required to receive the enclosed Medication Guide.
1 Single-Dose Autoinjector. Discard after use.
Rx only
Genentech
11044874

Unchanged: Contraindications, Warnings and precautions, Nonclinical toxicology, Untitled section, PRINCIPAL DISPLAY PANEL - 120 mg/mL Syringe Carton, PRINCIPAL DISPLAY PANEL - 120 mg/mL Autoinjector Carton.

Every version

11 versions of set 64c156a4-9bad-4d45-a294-0733c141f47b, newest first.
VersionPublished on DailyMedCompareSPL file
16Oct 30, 2026Shown belowDownload .zip
15Jun 24, 2026With version 13Download .zip
13Dec 19, 2025With version 10Download .zip
10May 15, 2025With version 9Download .zip
9Jul 14, 2023With version 8Download .zip
8Dec 22, 2022With version 7Download .zip
7Apr 28, 2022With version 6Download .zip
6Mar 16, 2022With version 5Download .zip
5Jul 28, 2021With version 4Download .zip
4May 17, 2021With version 2Download .zip
2Aug 26, 2020First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.